PANITUMUMAB

N/A

Manufactured by Amgen, Inc

31,648 FDA adverse event reports analyzed

Last updated: 2026-04-14

About PANITUMUMAB

PANITUMUMAB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Amgen, Inc. The most commonly reported adverse reactions for PANITUMUMAB include RASH, DIARRHOEA, DERMATITIS ACNEIFORM, DEATH, NEUTROPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PANITUMUMAB.

Top Adverse Reactions

RASH1,722 reports
DIARRHOEA1,526 reports
DERMATITIS ACNEIFORM1,005 reports
DEATH908 reports
NEUTROPENIA886 reports
SKIN TOXICITY850 reports
HYPOMAGNESAEMIA793 reports
NAUSEA780 reports
DISEASE PROGRESSION712 reports
NEUROPATHY PERIPHERAL688 reports
COLORECTAL CANCER METASTATIC625 reports
FATIGUE625 reports
OFF LABEL USE604 reports
VOMITING598 reports
STOMATITIS573 reports
PARONYCHIA563 reports
THROMBOCYTOPENIA559 reports
DRY SKIN544 reports
DECREASED APPETITE527 reports
ASTHENIA517 reports
ANAEMIA490 reports
PYREXIA483 reports
THERAPY PARTIAL RESPONDER428 reports
METASTASES TO LIVER400 reports
ERYTHEMA396 reports
PRURITUS393 reports
INTERSTITIAL LUNG DISEASE370 reports
DYSPNOEA353 reports
MUCOSAL INFLAMMATION314 reports
RASH PUSTULAR311 reports
SKIN DISORDER311 reports
FEBRILE NEUTROPENIA307 reports
DEHYDRATION304 reports
ACNE284 reports
MALAISE283 reports
ABDOMINAL PAIN279 reports
SKIN REACTION268 reports
PULMONARY EMBOLISM260 reports
COLON CANCER259 reports
SKIN FISSURES256 reports
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME239 reports
HYPERSENSITIVITY237 reports
GENERAL PHYSICAL HEALTH DETERIORATION236 reports
POLYNEUROPATHY232 reports
HYPOKALAEMIA229 reports
MALIGNANT NEOPLASM PROGRESSION228 reports
NEUTROPHIL COUNT DECREASED228 reports
HYPERTENSION227 reports
LEUKOPENIA217 reports
WEIGHT DECREASED216 reports
DRUG INEFFECTIVE211 reports
COLORECTAL CANCER210 reports
PAIN210 reports
CONSTIPATION205 reports
PRODUCT STORAGE ERROR199 reports
PNEUMONIA191 reports
CONJUNCTIVITIS187 reports
ALOPECIA185 reports
URINARY TRACT INFECTION185 reports
NEUROTOXICITY180 reports
METASTASES TO LUNG178 reports
HYPOCALCAEMIA177 reports
SKIN LESION177 reports
SEPSIS165 reports
HYPOTENSION164 reports
ACUTE KIDNEY INJURY161 reports
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR159 reports
INFECTION159 reports
PLATELET COUNT DECREASED157 reports
SKIN EXFOLIATION150 reports
BLOOD MAGNESIUM DECREASED147 reports
INFUSION RELATED REACTION143 reports
WHITE BLOOD CELL COUNT DECREASED143 reports
BACK PAIN139 reports
DERMATITIS131 reports
RASH MACULO PAPULAR128 reports
DEEP VEIN THROMBOSIS127 reports
FOLLICULITIS127 reports
PERIPHERAL SENSORY NEUROPATHY127 reports
INTESTINAL OBSTRUCTION124 reports
DIZZINESS121 reports
CONDITION AGGRAVATED119 reports
CHILLS118 reports
TOXICITY TO VARIOUS AGENTS114 reports
HAEMOGLOBIN DECREASED110 reports
NEOPLASM PROGRESSION110 reports
RENAL FAILURE110 reports
HEADACHE109 reports
ASCITES108 reports
EPISTAXIS107 reports
PARAESTHESIA105 reports
COVID 19104 reports
ADENOCARCINOMA OF COLON97 reports
CHEST PAIN94 reports
ILEUS94 reports
HEPATIC FAILURE91 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE90 reports
HAEMATOTOXICITY87 reports
OEDEMA PERIPHERAL86 reports
ALANINE AMINOTRANSFERASE INCREASED85 reports

Report Outcomes

Out of 14,672 classified reports for PANITUMUMAB:

Serious 86.8%Non-Serious 13.2%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male7,644 (62.2%)
Female4,569 (37.2%)
Unknown80 (0.7%)

Reports by Age

Age 67407 reports
Age 70381 reports
Age 66350 reports
Age 68338 reports
Age 62336 reports
Age 65333 reports
Age 69305 reports
Age 64300 reports
Age 71300 reports
Age 61278 reports
Age 63278 reports
Age 74278 reports
Age 60271 reports
Age 73271 reports
Age 72261 reports
Age 59259 reports
Age 57258 reports
Age 58256 reports
Age 75246 reports
Age 8209 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with PANITUMUMAB?

This profile reflects 31,648 FDA FAERS reports that mention PANITUMUMAB. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for PANITUMUMAB?

Frequently reported terms in FAERS include RASH, DIARRHOEA, DERMATITIS ACNEIFORM, DEATH, NEUTROPENIA, SKIN TOXICITY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures PANITUMUMAB?

Labeling and FAERS entries often list Amgen, Inc in connection with PANITUMUMAB. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.